Literature DB >> 27803501

Medication Therapy Management for Patients Receiving Oral Chemotherapy Agents at a Community Oncology Center: A Pilot Study.

Nathan S Bertsch, Ross J Bindler, Poppy L Wilson, Anne P Kim, Beverly Ward.   

Abstract

Purpose: To determine the impact of a pharmacist-driven medication therapy management (MTM) program for patients receiving oral chemotherapy agents.
Methods: We assessed the impact of MTM consultations with a pharmacist for patients who were receiving a new prescription for an oral chemotherapy agent. Data were assessed for outcomes including (1) number of medication errors identified in electronic medical records (EMRs), (2) number of interventions performed by the pharmacist, (3) time spent on the MTM process, and (4) patient satisfaction. Data were compared between patients who received their oral chemotherapy agents from the onsite specialty pharmacy or from a mail-order pharmacy. The data were also examined for correlations, and logistic regression was utilized to determine the largest variant cofactor to create an equation for estimating the number of errors in a patient's EMR.
Results: Fifteen patients received an MTM consultation, and the pharmacists identified an average of 6 medication EMR errors per patient. There was an average of 3 pharmacist-led interventions per patient. Multiple significant correlations were noted between the variables: (1) total number of prescriptions a patient was taking, (2) total number of medication errors identified, (3) time spent on the MTM process, and (4) total number of interventions performed by the pharmacist. Patient satisfaction was favorable for the program.
Conclusion: The implementation of a pharmacist-driven MTM program for patients receiving a prescription for an oral chemotherapy agent had a significant impact on patient care by improving medication reconciliation, identifying drug-related problems, and strengthening pharmacist-patient interactions in the oncology clinic.

Entities:  

Keywords:  MTM; chemotherapeutics; medication therapy management; oral antineoplastic agents; oral chemotherapeutics; oral chemotherapy agents

Year:  2016        PMID: 27803501      PMCID: PMC5080990          DOI: 10.1310/hpj5109-721

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  20 in total

1.  Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice.

Authors:  Lisa M Holle; Sonam Puri; Jessica M Clement
Journal:  J Oncol Pharm Pract       Date:  2015-04-21       Impact factor: 1.809

2.  Medication safety of five oral chemotherapies: a proactive risk assessment.

Authors:  Saul N Weingart; Justin Spencer; Stephanie Buia; Deborah Duncombe; Prabhjyot Singh; Mrinalini Gadkari; Maureen Connor
Journal:  J Oncol Pract       Date:  2010-12-08       Impact factor: 3.840

Review 3.  Oral chemotherapy food and drug interactions: a comprehensive review of the literature.

Authors:  Eve M Segal; Megan R Flood; Robert S Mancini; Robert T Whiteman; Gregory A Friedt; Adam R Kramer; Mark A Hofstetter
Journal:  J Oncol Pract       Date:  2014-04-22       Impact factor: 3.840

4.  The Global Burden of Cancer 2013.

Authors:  Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

Review 5.  Does applying technology throughout the medication use process improve patient safety with antineoplastics?

Authors:  Joseph Bubalo; Bruce A Warden; Joshua J Wiegel; Tess Nishida; Evelyn Handel; Leanne M Svoboda; Lam Nguyen; P Neil Edillo
Journal:  J Oncol Pharm Pract       Date:  2013-12-19       Impact factor: 1.809

6.  Early discontinuation of tamoxifen: a lesson for oncologists.

Authors:  Thomas I Barron; Róisín Connolly; Kathleen Bennett; John Feely; M John Kennedy
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

Review 7.  Oral chemotherapeutic agents for colorectal cancer.

Authors:  S Sharma; L B Saltz
Journal:  Oncologist       Date:  2000

8.  Pharmacy benefit spending on oral chemotherapy drugs.

Authors:  Frederic R Curtiss
Journal:  J Manag Care Pharm       Date:  2006-09

Review 9.  Patient adherence and persistence with oral anticancer treatment.

Authors:  Kathryn Ruddy; Erica Mayer; Ann Partridge
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

10.  The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?

Authors:  Phyllis M Lau; Kay Stewart; Michael Dooley
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

View more
  5 in total

1.  Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.

Authors:  Ariel L Hernandez; Ying Wang; Hilary L Somerset; Stephen B Keysar; Dara L Aisner; Carrie Marshall; Daniel W Bowles; Sana D Karam; David Raben; Antonio Jimeno; Marileila Varella-Garcia; Xiao-Jing Wang
Journal:  Mol Carcinog       Date:  2019-01-16       Impact factor: 4.784

2.  PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.

Authors:  Ariel L Hernandez; Christian D Young; Li Bian; Kelsey Weigel; Kyle Nolan; Barbara Frederick; Gangwen Han; Guanting He; G Devon Trahan; Michael C Rudolph; Kenneth L Jones; Ayman J Oweida; Sana D Karam; David Raben; Xiao-Jing Wang
Journal:  Clin Cancer Res       Date:  2020-03-05       Impact factor: 12.531

3.  Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations.

Authors:  Gennaro A Paolella; Andrew D Boyd; Scott M Wirth; Sandra Cuellar; Neeta K Venepalli; Stephanie Y Crawford
Journal:  Pharmacy (Basel)       Date:  2018-03-08

4.  2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard.

Authors:  Emily Mackler; Eve M Segal; Benyam Muluneh; Kate Jeffers; Jenna Carmichael
Journal:  J Oncol Pract       Date:  2019-03-12       Impact factor: 3.840

5.  Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.

Authors:  Christina A Spivey; Junling Wang; Yanru Qiao; Ya-Chen Tina Shih; Jim Y Wan; Julie Kuhle; Samuel Dagogo-Jack; William C Cushman; Marie Chisholm-Burns
Journal:  J Manag Care Spec Pharm       Date:  2018-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.